HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dermafile

This article was originally published in The Rose Sheet

Executive Summary

Aesthetician brand launches Dermafile Body, a tool "for exfoliating and polishing away rough skin, signs of sun damage, stretch marks and more," according to Sept. 8 announcement. Product is made with surgical-grade stainless steel and "finely crushed cosmetic diamonds." It will be available in both professional-strength and at-home versions in December for $39.95 at Dermafile.com, the Tampa, Fla.-based company says

You may also be interested in...



Alleged ‘Pink Tax’ Class Actions Against OTC Personal-Care Brands Moving Through Federal Courts

Walgreen Co. seeks to dismiss allegations in California’s Northern District that it unlawfully charges more for its OTC Hair Regrowth Treatment for women compared with a “functionally equivalent” offering for men. The suit follows “pink tax” litigation concerning Dove antiperspirants that defendants dismissed in July 2020, a decision affirmed by the Eighth Circuit in May.

Lumakras A Big Focus For Amgen; More Data Coming Soon

Amgen reported 5% year-over-year revenue growth to $6.5bn in the second quarter, up 11% from Q1. It did not break out Lumakras sales but detailed upcoming data that may support future indications.

Medicare Coverage With Evidence Development Mandate Expires After Four Years Under Senate Bill

As CMS brings public attention to process with its national coverage analysis for Alzheimer’s drugs, legislation aims to encourage quick recommendations – and strengthen collaboration with FDA.

UsernamePublicRestriction

Register

RS016407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel